Published in

Newlands Press, Future Medicinal Chemistry, 8(9), p. 749-764, 2017

DOI: 10.4155/fmc-2017-0029

Links

Tools

Export citation

Search in Google Scholar

Chalcone-based carbamates for Alzheimer’s disease treatment

This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Green circle
Postprint: archiving allowed
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

Aim: Alzheimer’s disease is a still untreatable multifaceted pathology, and drugs able to stop or reverse its progression are urgently needed. In this picture, the recent reformulation of the cholinergic hypothesis renewed the interest for acetylcholinesterase inhibitors. In this paper, a series of naturally inspired chalcone-based carbamates was designed to target cholinesterase enzymes and possibly generate fragments endowed with neuroprotective activity in situ. Results & methodology: All compounds presented in this study showed nanomolar potency for cholinesterase inhibition. Notably, fragment 11d also displayed an interesting neuroprotective profile. Conclusion: These new derivatives are able to simultaneously modulate different key targets involved in Alzheimer’s disease, and could be regarded as promising starting points for the development of disease-modifying drug candidates. [Formula: see text]